A phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors

被引：0
|
作者：
Ji, Dongmei
Weitao, Yao
Tong, Xiangmin
Zhang, Chenping
Wang, Feng
Chen, Zhendong
Zhou, Yuhong
Li, Zhendong
Deng, Yaotiao
Huang, Gang
Tao, Zhiwei
Zheng, Yulong
Wang, Gang
Liu, Guowen
Chen, Jing
Niu, Xiaohui
Yang, Jilong
Pang, Weijia
Zhao, Min
Hu, Xichun
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Orthoped, Zhengzhou, Peoples R China
[3] Henan Canc Hosp, Zhengzhou, Peoples R China
[4] ZheJiang Prov Peoples Hosp, Dept Hematol, Hangzhou, Peoples R China
[5] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Oral & Maxillofacial Head & Neck Oncol, Shanghai, Peoples R China
[6] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[7] Anhui Med Univ, Affiliated Hosp 2, Dept Oncol, Hefei, Peoples R China
[8] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Shanghai, Peoples R China
[9] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[10] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China
[11] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Hosp,Dept Orthoped & Soft Tissue, Changsha, Peoples R China
[12] Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China
[13] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[14] Univ Sci & Technol China, Affiliated Hosp 1, Hefei, Peoples R China
[15] Shenzhen Second Peoples Hosp, Shenzhen, Peoples R China
[16] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China
[17] Beijing Jishuitan Hosp, Beijing, Peoples R China
[18] Beijing Jishuitan Hosp, Beijing, Peoples R China
[19] Tianjin Canc Inst & Hosp, Tianjin, Peoples R China
[20] ImmVira Co Ltd, Shenzhen, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2520
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Updated results from an ongoing phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via IT injection as monotherapy or combined with pembrolizumab in advanced solid tumors.
    Niu, Jiaxin
    Kaufman, Howard L.
    Kichenadasse, Ganessan
    Haydon, Andrew Mark
    Barve, Minal A.
    Ganju, Vinod
    Buchbinder, Elizabeth Iannotti
    Spira, Alexander I.
    Pang, Weijia
    Fu, Wenmin
    Zhao, Min
    Kirkwood, John M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Intravenous (IV) infusion of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, as monotherapy in advanced solid tumors: Preliminary results from an ongoing phase 1/2a study
    Niu, Jiaxin
    Barve, Minal A.
    Spira, Alexander I.
    Edenfield, William Jeffery
    Pang, Weijia
    Fu, Wenmin
    Lu, Yingxin
    McKean, Meredith
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Intravenous infusion (IV) or intracavitary perfusion (IP) of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody: Analyses of two phase 1 studies.
    Niu, Jiaxin
    Barve, Minal A.
    Spira, Alexander I.
    Edenfield, William Jeffery
    Wang, Kevin
    Liu, Gaiyun
    McKean, Meredith
    Fu, Wenmin
    Qiu, Meng
    Cheng, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] A phase I/IIa study to assess the safety, tolerability, PK, and PD of T3011, a genetically modified oncolytic virus (OVs) administered intravenously (IV) in patients with advanced solid tumors
    Li, Ziming
    Zhang, Jian
    Zhang, Shuang
    Zheng, Li
    Zhang, Zhiye
    Wang, Junbin
    Hu, Ying
    Luo, Su-xia
    Pang, Weijia
    Fu, Wenmin
    Qin, Yanmei
    Lu, Shun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
    Shen, Y.
    Rahimian, S.
    Qin, A.
    Qiu, Y.
    Fang, T.
    Liang, X.
    Li, Y.
    Tan, Q.
    Zhao, R.
    Bai, X.
    Liang, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S1499 - S1499
  • [6] The initial report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
    Fu, Siqing
    Kundranda, Madappa N.
    Rahimian, Shah
    Shen, Yinan
    Tan, Qian
    Zhao, Ronghua
    Esmaeili, Naghmeh
    Singh, Manu
    Ding, Jun
    Murad, Yanal
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/Ra payloads, in patients with advanced solid tumors
    Shen, Y.
    Rahimian, S.
    Qin, A.
    Qiu, Y.
    Fang, T.
    Liang, X.
    Li, Y.
    Tan, Q.
    Zhao, R.
    Bai, X.
    Liang, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S677 - S677
  • [8] Envafolimab - first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors
    Chen, Mifen
    Jiang, Mengyun
    Wang, Xinhui
    Shen, Lin
    Li, Jian
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (10) : 1227 - 1232
  • [9] A phase I study of AK112, a bispecific antibody that targets PD-1 and VEGF co-expressing T cells, in patients with advanced solid tumors.
    Coward, Jermaine
    Lemech, Charlotte Rose
    Mislang, Anna Rachelle Austria
    Parakh, Sagun
    Underhill, Craig
    Nagrial, Adnan
    Jin, Xiaoping
    Li, Baiyong
    Wang, Zhongmin Maxwell
    Kwek, Kon Yew
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] PHASE I STUDY OF ANTI PD-1 ANTIBODY ONO-4538 IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Yamamoto, N.
    Nokihara, H.
    Yamada, Y.
    Asahina, H.
    Shibata, T.
    Tamura, Y.
    Seki, Y.
    Honda, K.
    Tanabe, Y.
    Wakui, H.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 26 - 26
12345